BEVERLY HILLS, Calif., June 16 /PRNewswire-FirstCall/ -- OXIS International, Inc. (OTC Bulletin Board: OXIS, Paris: OXI), announced today the appointment of Sandep Rahi as CSO (Chief Strategist) and brand rollout advisor beginning immediately. Sandep is an EMMY award-winning Creative Director seasoned in both the entertainment and advertising industries. He has extensive experience establishing and overseeing strategic creative development and implementation for emerging and existing global brands while maintaining close collaborative relationships with key stakeholders. Over the years he has led creative teams on design and branding projects for networks such as ABC, NBC, CBS, FOX and ESPN. Additionally Mr. Rahi has been a creative force for brands such as Glaceau, Ford Motor Company, Daimler Chrysler, Mazda, Hershey's, KFC, T-Mobile and Verizon.
Currently Sandep is SVP, Group Creative Director at Dentsu, where he has led his teams to develop advertising campaigns across all media for brands including Union Bank, Bandai, Chandon, Chapman University, Famima!!, Hass Avocados, MLS, NovaLogic and Nissan Foods (maker of Yakult the world's leading Probiotic beverage).
Chairman/CEO Anthony Cataldo stated, "The addition of Mr. Rahi is a coup for OXIS and its shareholders. He provides us the creative and intellectual horsepower of a global firm. In his role he will advise the company on its much anticipated US and International products rollout plan that was announced recently at the Rodman & Renshaw Global Investment Conference in London."
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.
SOURCE OXIS International, Inc.